可溶性fms样酪氨酸激酶1在子痫前期胎盘中的表达及意义

[Expression and significance of soluble fms-like tyrosine kinase 1 in preeclampsia placenta].

作者信息

Ye Yuan-hua, Liu Ling, Zhan Ying, Peng Wei

机构信息

Department of Obstetrics, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, China.

出版信息

Zhonghua Fu Chan Ke Za Zhi. 2006 Aug;41(8):521-4.

PMID:17083834

Abstract

OBJECTIVE

To investigate the expression and significance of serum soluble fms-like tyrosine kinase 1 (sFlt-1) in preeclampsia placenta.

METHODS

Immunohistochemistry and semi-quantitative RT-PCR were used to investigate the expression of sFlt-1 and sFlt-1 mRNA in placenta of 30 women with preeclampsia (including mild and moderate preeclampsia 11 cases, severe preeclampsia 19 cases) and 45 normal pregnant women (including first trimester pregnancy 18 cases, 2nd trimester pregnancy 12 cases, and 3rd trimester pregnancy 15 cases). The levels of vascular endothelial growth factor (VEGF) and sFlt-1 in serum were detected by enzyme linked immunosorbent assay.

RESULTS

(1) The expression of sFlt-1 mRNA was significantly higher in preeclampsia group (0.90 +/- 0.11) compared with the third trimester group (0.80 +/- 0.06; P < 0.01), and was higher in the severe preeclampsia group (0.93 +/- 0.12) than that in the mild group (0.85 +/- 0.05; P < 0.05). (2) The mean density of sFlt-1 in preeclampsia placenta (0.156 +/- 0.008) was significantly higher than that in the third trimester group (0.143 +/- 0.009, P < 0.01), and was higher in the severe group (0.159 +/- 0.008) than in the mild group (0.151 +/- 0.005; P < 0.05). (3) The level of VEGF in serum of the preeclampsia group (19.3 +/- 2.9) ng/L was significantly lower than that of the third trimester group [(30.2 +/- 3.1) ng/L, P < 0.01]. The level of sFlt-1 in serum of the preeclampsia group (30.2 +/- 13.7) microg/L was significantly higher than that of the third trimester group [(7.4 +/- 3.1) microg/L, P < 0.01]. (4) There was significant correlation between the serum level of sFlt-1 and the expression of sFlt-1 mRNA or sFlt-1 in placenta of normal pregnancy group (r = 0.314, P < 0.05; r = 0.439, P < 0.01) and preeclampsia groups (r = 0.372, r = 0.383; P < 0.05).

CONCLUSION

Upregulation of sFlt-1mRNA and excess expression of sFlt-1 in placenta may induce higher level of sFlt-1 in serum, which may be involved in the pathophysiological processes of preeclampsia.

摘要

目的

探讨血清可溶性fms样酪氨酸激酶1（sFlt-1）在子痫前期胎盘组织中的表达及意义。

方法

采用免疫组化法和半定量逆转录聚合酶链反应（RT-PCR）检测30例子痫前期患者（其中轻度及中度子痫前期11例，重度子痫前期19例）及45例正常孕妇（其中孕早期18例，孕中期12例，孕晚期15例）胎盘组织中sFlt-1及sFlt-1 mRNA的表达。采用酶联免疫吸附测定法检测血清中血管内皮生长因子（VEGF）和sFlt-1水平。

结果

（1）子痫前期组sFlt-1 mRNA表达水平（0.90±0.11）显著高于孕晚期组（0.80±0.06；P<0.01），且重度子痫前期组（0.93±0.12）高于轻度子痫前期组（0.85±0.05；P<0.05）。（2）子痫前期胎盘组织中sFlt-1平均密度（0.156±0.008）显著高于孕晚期组（0.143±0.009，P<0.01），且重度组（0.159±0.008）高于轻度组（0.151±0.005；P<0.05）。（3）子痫前期组血清VEGF水平（19.3±2.9）ng/L显著低于孕晚期组[（30.2±3.1）ng/L，P<0.01]。子痫前期组血清sFlt-1水平（30.2±13.7）μg/L显著高于孕晚期组[（7.4±3.1）μg/L，P<0.01]。（4）正常妊娠组及子痫前期组血清sFlt-1水平与胎盘组织中sFlt-1 mRNA或sFlt-1表达均呈显著正相关（正常妊娠组：r=0.314，P<0.05；r=0.439，P<0.01；子痫前期组：r=0.372，r=0.383；P<0.05）。